Shots:
The four P-III (TENAYA & LUCERNE) & (YOSEMITE & RHINE DME) studies evaluate the efficacy & safety of faricimab vs aflibercept in 1329 & 1891 patients with wet AMD & DME
The trials met the 1EPs i.e., patients achieved non-inferior vision gains, ~50% of patients were able to go 4mos. in 1st yr. while three-quarters could be treated q3mos., reduction in CST & CNV lesion size and area, was generally well-tolerated with a favorable benefit-risk profile
Faricimab is currently under US FDA’s review for wet AMD and DME. The EMA is also currently evaluating the faricimab’s MAA for the same indication. Additionally, the (COMINO) & (BALATON) trials are underway for macular edema following retinal vein occlusion
Ref: Businesswire | Image: BioSpace
